{"entity":{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","aka":[],"tldr":"A phase 3 trial testing AL2846 in thyroid cancer, now recruiting.","summary":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma is a phase 3 interventional study registered as NCT06860971, led by Chia Tai Tianqing Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy. Planned enrolment is 144 participants (estimated). The study started in 2025-04-18 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06860971","url":"https://clinicaltrials.gov/study/NCT06860971"}],"tags":["ctgov-ingest"],"related":[],"cancers":["thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":["al2846"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06860971","phase":"3","setting":"A Randomized, Double-Blind, Multicenter Phase III Clinical Trial Evaluating AL2846 Capsule Versus Placebo in Patients With Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Who Failed Prior VEGFR-Targeted Therapy","sponsor":"Chia Tai Tianqing Pharmaceutical","participation":[{"nct":"NCT06860971","source":"https://clinicaltrials.gov/study/NCT06860971","fetchedAt":"2026-10-07T16:55:12.940Z","studySha256":"aa9ac282e0fc6d0f60a5b4e0842f72550cf4658e85e299e3ebc446095dc94a9c","overallStatus":"RECRUITING","lastUpdatePosted":"2025-12-31","leadSponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":144,"enrolmentType":"ESTIMATED","siteCount":35,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-04-18","startedType":"actual","enrolled":144,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06860971/","neighbours":{"cancer":[{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"drug":[{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}